1. Home
  2. PLUS vs AMLX Comparison

PLUS vs AMLX Comparison

Compare PLUS & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ePlus inc.

PLUS

ePlus inc.

HOLD

Current Price

$85.95

Market Cap

2.2B

Sector

Technology

ML Signal

HOLD

Logo Amylyx Pharmaceuticals Inc.

AMLX

Amylyx Pharmaceuticals Inc.

HOLD

Current Price

$17.65

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLUS
AMLX
Founded
1990
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
PLUS
AMLX
Price
$85.95
$17.65
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$20.11
AVG Volume (30 Days)
145.8K
1.2M
Earning Date
05-21-2026
05-07-2026
Dividend Yield
1.17%
N/A
EPS Growth
N/A
65.46
EPS
4.08
N/A
Revenue
$2,068,789,000.00
$380,786,000.00
Revenue This Year
$19.83
N/A
Revenue Next Year
$4.36
N/A
P/E Ratio
$20.88
N/A
Revenue Growth
N/A
1612.94
52 Week Low
$58.39
$4.41
52 Week High
$93.98
$18.61

Technical Indicators

Market Signals
Indicator
PLUS
AMLX
Relative Strength Index (RSI) 66.24 64.35
Support Level $85.63 $13.19
Resistance Level $91.86 N/A
Average True Range (ATR) 2.61 0.91
MACD 0.90 0.26
Stochastic Oscillator 97.75 83.26

Price Performance

Historical Comparison
PLUS
AMLX

About PLUS ePlus inc.

ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.

About AMLX Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Share on Social Networks: